DiscoDivas: Leveraging genetic ancestry continuum information to interpolate PRS for admixed populations

Yunfeng Ruan[1], Rohan Bhukar[1,2], Aniruddh Patel[1,2,3], Satoshi Koyama[1,2,3,4], Leland Hull[5,6], Buu Truong[1,2,3,7], So Mi Cho[1,2,8], Whitney Hornsby[1,2], Haoyu Zhang[9], Nilanjan Chatterjee[10,11], Pradeep Natarajan[1,2,3,6]

Affiliations:
1. Program in Medical and Population, Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA
2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
3. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, USA
4. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
5. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
6. Department of Medicine, Harvard Medical School, Boston, MA, USA
7. Department of Genetic Epidemiology and Statistical Genetics, Harvard T.H. School of Public Health, Cambridge, MA, US
8. Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea
9. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
10. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
11. Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Please address correspondence to:
Pradeep Natarajan, MD MMSc
185 Cambridge Street, CPZN 5.238
Boston, MA 02446
617-726-1843
pnatarajan@mgh.harvard.edu

Summary

The relatively low representation of admixed populations in both discovery and fine-tuning individual-level datasets limits polygenic risk score (PRS) development and equitable clinical translation for admixed populations. Under the assumption that the most informative PRS model for a genetically homogeneous sample varies linearly in an ancestry continuum space, we introduce a Genetic **Dis**tance-assisted PRS **Co**mbination Pipeline for **Div**erse Genetic **A**ncestrie**s** (**DiscoDivas**) to interpolate a harmonized PRS for diverse, especially admixed, genetic ancestries, leveraging multiple PRS models fine-tuned within existing samples, which are mostly of single ancestry, and genetic distance. DiscoDivas treats genetic ancestry as a continuous variable and does not require shifting between different models when calculating PRS for different ancestries. We generated PRS with DiscoDivas and the current conventional method, i.e. fine-tuning multiple GWAS PRS using the matched or similar genetic ancestry samples. DiscoDivas generated a harmonized PRS of the accuracy comparable to or higher than the conventional approach, with the greatest advantage exhibited in admixed individuals.

Keywords

polygenic risk score (PRS); admixed population; PRS harmonization; principal component analysis (PCA); genetic distance; genetic ancestry continuum

Introduction

Individuals who are not of European ancestries remain underrepresented in genome-wide association studies (GWAS), which at least partly explains why polygenic risk score (PRS) performance is generally reduced in this population when compared with individuals of European ancestries[1]. Within the constraints of existing data, the current principal solution to increase the PRS accuracy among non-European individuals is to fine-tune a combination of PRS derived from multiple populations or multiple traits with the individual-level data of a training cohort[2–6]. However, PRS accuracy decays as the genetic distance between the fine-tuning and testing samples increases[7]. Relative to the vast diversity across the genetic ancestry continuum, the existing and near-term individual-level datasets that can be used for fine-tuning PRS combinations remains very sparse. Most existing individual-level genotype data are mainly collected from single-ancestry populations and therefore admixed populations are left underrepresented or are largely excluded from analysis [8–11]. Additionally, fine-tuning and testing samples that are labeled as "from the same superpopulation" are often truly genetically heterogeneous [10,12–15], leading to variable accuracy within such samples.

PRS analysis across diverse ancestries may also be limited by inconsistency. The raw PRS distributions of the same model varies by ancestry and therefore the raw PRS values for individuals of different genetic ancestries should not be directly compared without ancestry correction[16–18]. Although prior research[16,18,19] has shown that regressing out the top principal components (PCs) of ancestry from the PRS can unify the PRS distributions of different ancestries (i.e., the mean and standard deviation of corrected PRS sampled from different populations can become very

85   close), the accuracy of one PRS model still varies across different genetic ancestries.
86   In the application of PRS across diverse ancestries, one would have to use one PRS
87   model for all the individuals, causing inconsistent PRS accuracy, or use several
88   discrete PRS models for different individuals approximating superpopulations also
89   causing inconsistent PRS modelling and accuracy.
90
Given these issues and the increasing clinical use of PRS[20–22], PRS generation for
diverse and admixed genetic ancestries with more consistent accuracy and more
unified PRS distributions is critically needed. Several methods have been developed
to incorporate local ancestry inference information into PRS models to increase
prediction accuracy in admixed populations[23,24]. However, the effectiveness of these
approaches is constrained by the lack of widely accepted standards for local ancestry
analysis, accuracy of local ancestry inference, and by their reliance on reference
panels[25,26]. Moreover, methods for fine-tuning PRS models have advanced rapidly in
recent years, including utilizing summary-level genetic data[27]. The advances in PRS
methods and the on-going effort to collect genetic data from diverse populations
allow PRS to be trained in cohorts with ancestry profiles that differ from those of the
reference panels, presenting challenges for reference-dependent methods to fully
utilize these models. Finally, if causal SNPs and their effect sizes can be accurately
identified and estimated, neither observed marginal effect sizes across populations
nor PRS accuracy decay across populations may pose a challenge in constructing
PRS for diverse populations. However, the current genetic data for many traits is
insufficient to reach this ideal. Therefore, it remains important to consider population
differences and the notion of PRS accuracy decay with genetic distance remains
essential when constructing PRS across multiple populations.
110
111
In light of the present challenges and opportunities, we devised a method,
DiscoDivas, a Genetic *Dis*tance-assisted PRS *Co*mbination Pipeline for *Div*erse
Genetic *A*ncestrie*s*, to generate PRS across the genetic ancestry continuum directly
from the fine-tuning cohorts, which eliminates the need to align individuals with
external reference panels and further enhances PRS performance beyond what is
achieved by existing methods based on a single fine-tuning dataset. This method is
based on the recent observations[7,28] that the PRS accuracy in the testing data
decays approximately linearly as the genetic distance between the fine-tuning data
and testing data increases, and that the genetic distance can be approximated by
Euclidean distance of PC based on the global ancestries[7]. Further support comes
from additional findings: accuracy of PRS model trained in European population
similarly declines linearly as the proportion of European genetic ancestry decreased
in African American testing samples[29] and that principal component of ancestry has
also used to determine genetic ancestry proportion[30]. Together, these observations
indicate that PCs can provide meaningful information for modeling and anticipating
PRS prediction accuracy, most plausibly via a linear relationship. Based on the
above observations, we assumed that the correlation of the most informative PRS
models for two samples of different ancestries drops linearly as the Euclidean
distance of global ancestry-based PCs between them increases, and therefore, the
most informative PRS model for a genetically homogenous sample can be linearly
interpolated from the currently available PRS models that are fine-tuned in the
ancestries surrounding it in the global ancestry-based PC space with the interpolation
coefficients mainly based on the Euclidean distance of the PCs.
135
136   In summary, DiscoDivas calculates PRS for diverse and admixed genetic ancestries,
137   whose currently available genetic data may not be sufficiently powerful alone to train
138   a PRS model, by linearly interpolating the multiple PRS fine-tuned in ancestries

139 whose genetic data are more available. We evaluated its performance in simulated
140 and empiric data.
141

Results

Overview of DiscoDivas

DiscoDivas combines PRS fine-tuned in different fine-tuning samples - generally from
different single-ancestry populations - to linearly interpolate PRS for individuals of
diverse genetic ancestries, treating ancestry as a continuous variable. Based on the
recent observations [7,28–30], we assumed that the best PRS model, i.e. a SNP effect
size vector, for an ancestry representation can be linearly interpolated from other
PRS models fine-tuned in other ancestries with the additional consideration of the
genetic distance between the samples (Figure 1).
151

Under the same principle of interpolating the PRS models, the best PRS for an
individual can be interpolated from several PRS calculated using the PRS models
fine-tuned in other ancestries for this individual. Since generating individual-specific
PRS models in a testing dataset causes redundant calculation and given the difficulty
of normalizing information from different datasets, we combine the PRS instead of
the SNP models. The PRS of individual i PRS_i in the testing sample is a linear
combination of PRS based on the PRS models fine-tuned in different fine-tuning
samples:

160
$$PRS_i = \sum w_{i,k} PRS_{i,k}$$
$$PRS_{i,k} = \overrightarrow{\beta_k} \cdot \overrightarrow{x_i}$$

Where $\overrightarrow{x_i}$ is the genotype vector of the testing individual i; $PRS_{i,k}$ is the PRS of
testing individual i calculated using the PRS model $\overrightarrow{\beta_k}$ fine-tuned in the fine-tuning
sample k; $w_{i,k}$ is the combination coefficient mainly based on the reciprocal of the
PC Euclidean distance between the testing individual i and median point of the fine-
tuning sample k $D_{i,k}$. Note that the input PRS and PCs should be properly
harmonized: all the individuals are projected onto the same PC space based on a
global ancestry reference panel and the PRS input $PRS_{i,k}$ is the raw PRS regressed
out the top PCs and then standardized to mean = 0 and sd =1. Additionally, we
recommend including all available discovery GWAS when generate the input PRS
$PRS_{i,k}$ to maximize the PRS accuracy, as indicated in Figure 1. Nevertheless,
DiscoDivas is a flexible framework that also accommodates input PRS $PRS_{i,k}$ derived
from different sets of discovery GWAS and even generated using different PRS
methods.
174

In addition to the PC distances, other factors are included in the model. First, since
some fine-tuning samples are more correlated than others (e.g., EAS and SAS are
more correlated than AFR and EUR), the combination coefficients should be further
modified by these correlations, which can also be extracted from the PC Euclidean
distances. Second, since PRS fine-tuned in each of the fine-tuning samples may be
of differing qualities (e.g., when the PRS model fine-tuned in different samples are
based on GWAS of different sample sizes or populations), the quality of the PRS
trained with each of the training data will vary and should be taken into account when

combining the PRS. Thus, the combination coefficient $w_{i,k}$ in the previous formula is
a function of multiple factors:

$$w_{i,k} = f\left(\frac{1}{D_{i,k}}, G, r_k\right)$$

185   where $\frac{1}{D_{i,k}}$ is the reciprocal of PC Euclidean distance between the individual i and the
186   fine-tuning sample k; G is the matrix of PC Euclidean distance between fine-tuning
187   samples; r_k is the parameter describing the quality of training fine-tuning samples. A
188   more detailed description of defining $w_{i,k}$ is given in the method section entitled
189   'Methodological Details of DiscoDivas'.
190
The PRS input for DiscoDivas in this study was the multi-GWAS PRS fine-tuned in
Africa (AFR), East Asian (EAS), European (EUR), and South Asian (SAS) fine-tuning
samples with the conventional method pipeline as mentioned in the following section
titled "Overview of multi-population GWAS PRS model"). The interpolation from these
four PRS is based on the PCA calculated using the 1000 Genomes[31] reference panel.
For most of the PRS analysis conducted in in the present study, the input PRS of
DiscoDivas are based on the same set of discovery GWAS and the fine-tuning
datasets are sufficiently large to generate a stable result. Therefore, we assumed
that all the input PRS can be viewed as of equal quality and their parameter for PRS
quality r_k can be viewed as a constant value in the present study.

 # Overview of multi-population GWAS PRS model

202
Figure 1: The workflow of comparing DiscoDivas with the existing method. Left: The ideal situation
203
for the existing method is to fine-tune a PRS model that contains multiple GWAS with matched fine-
204
tuning data, which is not currently available for many under-represented populations. Right: DiscoDivas
205
first fine-tunes the PRS in the available ancestries, which are currently AFR, EAS, EUR, and SAS, and
206
interpolates PRS for diverse ancestry groups based on these fine-tuned PRS. In this plot, POP refers to
207
any ancestry for which the PRS is to be calculated. The bottom 2 panels showed the PC distribution of
208
fine-tuning datasets (green circles) and the testing data (orange circles). While more PCs were used in
209
the analysis, only PC1 and PC2 are shown here for clarity.
210

212
A common approach for constructing PRS is to include as much genome-wide
213
association study (GWAS) summary statistic data as possible in the discovery
214
data[5,32,33]. The GWAS data is typically then processed by PRS methods that will
215
adjust the SNP effect size using a set of hyper-parameters. Individual-level data of an
216
independent fine-tuning sample is used to fine-tune the hyper-parameters across
217
PRS methods and the combination of the fine-tuned PRS. The resulting PRS is
218
expected to perform the best in samples of matched ancestry with the fine-tuning
219
sample.
220

221
The current approach, as shown in the left panels of Figure 1, is to use the multi-
222
GWAS PRS fine-tuned in the matched sample or the closest approximation when the
223
matched sample is unavailable. The pipeline of adjusting SNP effect sizes and
224
combining information from different GWAS varies widely. Without loss of generality,

we built the following pipeline as a representation of the current conventional method:
we first adjusted the SNP effect size of each of the summary statistical GWAS
datasets by a Bayesian method and then chose the most predictive PRS from all the
PRS generated under different hyper-parameters. For simulated GWAS data, we
used PRS-CS[34] to adjust the SNP effect size and LDpred2[35] for real GWAS. Then
we used the fine-tuning data to first select the most predictive PRS based on each
GWAS and then to train the linear combination of the most predictive single-GWAS
PRS with a linear regression model. The final PRS model generated from each of the
fine-tuning datasets is a linear combination of PRS. For the empiric data set, the PRS
were fine-tuned controlling for the following covariates: top 20 PCA, sex, and age.
The Individuals from real-life biobanks and simulated individuals based on real-life
biobank genotype data were clustered into genetic ancestry Africa (AFR), East Asian
(EAS), European (EUR), South Asian (SAS), Admixed American (AMR), Individuals
not classified into any of these groups were labeled as Other (OTH). Depending on
data availability, either OTH or AMR was used to evaluate PRS performance in
admixed populations. In the conventional PRS generation pipeline, fine-tuning
datasets were drawn from the major ancestry groups (for single ancestry: AFR, EAS,
EUR, SAS; for admixed ancestry: OTH and/or AMR depending on availability). More
detailed description of generating PRS models from the one fine-tuning data was
given in supplementary method section entitled 'Methodological Details of PRS
Construction Using a Single Fine-tuning Dataset'.
246

Simulated data results

Summary-level GWAS used as discovery data were generated based on simulated
genotype of AFR, EAS, EUR, and SAS population based on 1000 Genomes[31]
reference as described in the previous publication provided by Zhang et al[6]. Fine-
tuning and testing samples were simulated based on UKBB genotype data. From
each ancestry group of AFR, EAS, EUR, SAS, and other (OTH) for admixed
individuals, 1300 individuals were used as the fine-tuning datasets (See
supplementary method section entitled 'Generating data for simulation analysis').
The phenotype of discovery, fine-tuning, and testing data were generated using the
same pipeline and parameters: the phenotypes of 100, 300, 1,000, or 10,000 causal
SNPs, a non-genetic factor following a normal distribution across populations and
global heritability = 0.6 were simulated. Scenarios of shared causal SNP with effect
size constant across different ancestries and shared causal SNP with effect size
varying across population are both simulated. We used up to 100,000 simulated
individuals from AFR, EAS, EUR, and SAS to generate the discovery summary
statistics GWAS dataset with PLINK2[36] and used 10,000 of the remaining samples
as fine-tuning dataset in other downstream analyses.
264
265 We primarily focused on the PRS performance in the OTH testing cohort. DiscoDivas,
266 which is based on PRS fine-tuned in AFR, EAS, EUR, and SAS, was compared with
267 the conventional PRS fine-tuned in the matched admixed fine-tuning sample in
268 scenarios of different causal SNP numbers, different discovery GWAS sample sizes,
269 and different causal SNP distribution across ancestry (See Figure 2)
270

271
Figure 2 Relative R^2 increase of DiscoDivas over the conventional PRS fine-tuned in a matched
sample when tested in admixed individuals. The x-axis shows the simulated number of causal SNPs.
The horizontal bar shows the mean relative R^2 increase and the color of the horizontal bar indicates the
p-value of the paired t-test of DiscoDivas PRS R^2 and conventional PRS R^2, with cyan being *p*-
value<0.0005, dark blue being *p*-value<0.05 and grey being *p*-value>0.05. In panels a, b, and c, the
causal SNP effect sizes are constant across different populations. The annotation texts on the top of
each panel shows the sample size of discovery GWAS of different populations and the distribution of
causal SNP effect sizes.

280
Although the comparison between DiscoDivas and the conventional method of fine-
tuning PRS with matched ancestry sample in a single test iteration usually showed
no statistical significance due to the small numeric differences, the paired t-test of
DiscoDivas R^2 and the conventional PRS R^2 over the 20 iterations better clarified
significant differences. When effect sizes of causal SNPs were held constant across
different ancestries (Figure 2 panel a, b, and c), the PRS generated by DiscoDivas
had comparable accuracy with the PRS fine-tuned using matched data. We noticed
that when the sample size of non-European discovery GWAS dropped and the
dataset was relatively more Eurocentric, the advantage of DiscoDivas became less
statistically significant. In Figure 2 panel d, we compared DiscoDivas and the
conventional PRS method of fine-tuning the PRS with matched ancestry in the
scenario where causal SNPs were shared across all populations, but the effect sizes
varied linearly in the PCA space. The advantage of DiscoDivas over conventional
PRS method was more obvious in this scenario than when the effect sizes were
constant across populations (Figure 2 panel d versus panel a), presumably because
personalized PRS combination with DiscoDivas better captured the changing effect
sizes for the admixed testing sample. In all the scenarios tested, the advantage of
DiscoDivas was least statistically significant when the number of causal SNPs was
10,000 but still significant when the number of causal SNPs was 1,000. Notably, the
accuracy of both DiscoDivas and the conventional PRS method was the lowest when
the number of causal SNPs was 10,000 (Supplementary Figure 1), indicating that the
difference of the two PRS methods became less obvious when the input data
became increasingly underpowered.
304
When predicting the individuals that are usually classified as single ancestries, i.e.
AFR, EAS, EUR, and SAS, DiscoDivas showed no statistically significant difference
or a slight advantage over the conventional PRS method (Supplementary Figure 2).
When predicting AMR individuals, we used admixed fine-tuning data (OTH) to fine-
tune the conventional PRS due to the small sample size of the AMR dataset. The
PRS performance when testing in the AMR dataset was similar as in admixed data
but the statistical significance was weaker, potentially due to the small sample size

and the high heterogeneity of the AMR dataset. Besides, DisocDivas showed its
clearest advantage over the conventional method of fine-tuning PRS with single
dataset when the testing data and the fine-tuning data for the conventional method
were of different ancestries (supplementary figure 2). This result underscores the
advantage of DiscoDivas in delivering a harmonized and robustly accurate PRS for
samples spanning a wide range of genetic ancestries, compared to relying on a
single PRS model or switching between multiple discrete PRS models.
319
320

Biobank data results

We downloaded publicly available summary statistical data of body-mass index (BMI),
high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL),
total cholesterol (TC), triglycerides (TG), systolic blood pressure (SBP), diastolic
blood pressure (DBP), coronary artery disease (CAD), and type 2 diabetes mellitus
(DM2) and adjusted the SNP effect size using LDpred2 as described previously[5].
327
For the quantitative traits, we used the fine-tuning samples of AFR, EAS, EUR, SAS,
and admixed (OTH) ancestry in the UK Biobank (UKBB) to fine-tune the model. The
remaining UKBB samples were used as the testing data. The results for empiric
quantitative trait data were highly aligned with the simulation results (Figure 3):
DiscoDivas showed a robust advantage over the conventional PRS method of fine-
tuning PRS with matched or similar ancestry samples when compared across the 7
traits in the OTH testing dataset. When predicting AFR, EAS, EUR, and SAS,
DiscoDivas and the conventional PRS method had similar or slightly improved
performance. The results of both methods in AMR testing dataset had large
deviations due to the small sample size and greater genetic heterogeneity of the
AMR data. Consistent with the simulated data, DiscoDivas showed a greater
advantage over PRS models fine-tuned on datasets of different ancestry from the
testing samples (Supplementary Figure 17). This further supports the potential of
DiscoDivas to construct a harmonized and robustly accurate PRS for individuals
across a wide range of ancestries.
343
344
345

347
Figure 3 Relative R^2 increase of DiscoDivas over the conventional PRS fine-tuned in a matched
sample. The x-axis shows the population in which the PRS was tested. We used OTH as the fine-tuning
dataset for the test in both OTH and AMR due to the absence of matched AMR training data. The
horizontal bar shows the mean of relative increase, and the line-type of the bar indicates the *p*-value of
paired t-test of DiscoDivas PRS R^2 and conventional PRS R^2, with the solid bar being *p*-value <0.05 and
dotted bar being *p*-value>0.05.

For the binary traits coronary artery disease (CAD) and type 2 diabetes (DM2)
(Figure 4), we used the AFR, EAS, EUR, SAS, AMR, and OTHsamples from All of
US Research (AoU) as the fine-tuning data and tested in AFR, EAS, EUR, SAS, and
OTH individuals in UKBB and AFR, EAS, EUR, SAS, and AMR individuals in MGBB.
The DiscoDivas PRS were based on the PRS fine-tuned in AFR, EAS, EUR, and
SAS and used the default assumption that the PRS fine-tuned from all the samples
were of similar quality even though the sample sizes of both discovery GWAS and
the fine-tuning samples were not balanced across different ancestries. AMR in UKBB
was excluded because of the small sample size (N=669).

The PRS fine-tuned in different single samples and the DiscoDivas PRS had similar
performances. It also appeared that some of the fine-tuning sample could be
underpowered: generally, we expect the PRS fine-tuned in the matched sample to
perform the best in the testing samples, but PRS fine-tuned in larger fine-tuning data
performed better than PRS fine-tuned in smaller fine-tuning data in general. For
example, the PRS fine-tuned in EAS AoU data performed worse than other PRS in
both MGBB and UKBB EAS data and had low accuracy in other testing data as well;
the CAD PRS fine-tuned in EUR performed better than all the other PRS in all the
testing data and the effective sample size of EUR CAD fine-tuning data was much
larger than all the other fine-tuning data.

376
Figure 4 PRS performance for coronary artery disease (CAD) and type 2 diabetes (DM2) tested in
UKBB and MGBB. The plot shows BETA, which is defined as ln(OR per SD) with the error bar showing
95% CI. The sub-panels show that population of the testing sample and the different colors show the
method for generating the PRS, either fine-tuning in a single sample or combining the PRS using
DiscoDivas.

Discussion

We propose a new method, DiscoDivas, to interpolate the PRS for diverse, especially
admixed, ancestries with a generalized framework that does not required binning into
discrete ancestries. Our results shows that the accuracy of DiscoDivas was

comparable to or greater than the conventional method, i.e. fine-tuning using the
matched population sample when available. In addition, when generating PRS for a
wide range of ancestries, DiscoDivas did not require shifting from several sets of
PRS models fine-tuned in discrete samples while remaining matched with the
ancestry information. Additionally, DiscoDivas is a flexible framework that allows
input PRS models to be generated using other advanced methods, further enhancing
the final PRS performance across diverse genetic ancestries. Our method provides a
new solution to generate PRS for underrepresented, generally admixed, populations
and as well as generate a harmonized PRS model across different ancestries.
396
The performance of our method depends on the quality of both the discovery GWAS
data and the fine-tuning data. As shown in the simulation test, discovery GWAS
datasets that represent diverse ancestries with sufficient sample size will increase
the accuracy of interpolated PRS generated by DiscoDivas. On the contrary,
Eurocentric and underpowered discovery GWAS datasets would limit the advantage
of DiscoDivas over the conventional PRS method. This might partly explain the
limited advantage of DiscoDivas when predicting binary traits: the discovery GWAS
datasets were highly Eurocentric and the GWAS, especially the non-European
cohorts, could be more underpowered than quantitative trait GWAS. Furthermore, the
PRS fine-tuned in fine-tuning datasets of insufficient sample size will be overfitted
and cannot be used to fairly evaluate the performance of either the conventional PRS
method or DiscoDivas. We aimed to address this issue by only using traits that 1)
had effective sample sizes larger than 200 in all the fine-tuning samples, and 2) had
high-quality phenotyping data in both the fine-tuning datasets and the testing
datasets, However, Asian populations were largely under-represented in the current
public biobanks: the effective sample size of many binary traits in EAS or SAS can be
as small as <200 even in AoU, the most diverse and large-scale largely publicly-
available biobank we had access to. This limited our choice for binary traits to only
CAD and DM2.
416
The difficulty of gathering data for our research underscores the notion that non-
European populations, both admixed and singe-ancestry populations, remain largely
under-represented in the existing genetic data. Furthermore, some potential
extensions of our method will not become possible until we collect more diverse and
larger datasets. First, our method has not been designed nor tested for extrapolating
data, e.g. generating PRS for continental African samples based on African American,
European, and Asian samples. Even though it is mathematically plausible to alter our
method to extrapolate the PRS, we lack data such as continental African samples to
test the method. Secondly, we currently only consider the assumption that the most
informative genome-wide PRS model shifts linearly in the PCA space. Although more
complicated PRS interpolation, e.g. interpolation guided by local ancestry information
[24,33,37], pathway-specific[39,40] and annotation-guided[41] PRS models and polynomial
interpolation[42,43], can possibly further improve the PRS accuracy, training such
complicated models would require collecting much larger and more diverse datasets
than the existing data. Finally, additional biological insights could be revealed by
interpolating PRS if genetic data of all the involved diverse ancestries are of sufficient
power. In this case, the differences between interpolated PRS and the PRS trained
using the matched ancestry would indicate the population- or sample- specific factors
absent in the interpolation model, e.g. population-specific genetic variance[44],
complicated population stratification involving cofounding factors[45,46],
sample/ancestry-specific modifiers like local adaptation[45], gene x environment
interactions[47] or other factors that contribute to the genetic variant frequency or effect
size in these samples/ ancestries.
440

DiscoDivas does not consider the local ancestry information, which improve PRS
predictions in various research[24,33,37], especially PRS prediction of newly admixed
populations[38]. This may result in suboptimal performance in newly admixed
populations. However, this design choice makes our method highly applicable and
robust in settings where the input PRS model are fine-tuned using cohorts whose
genetic ancestries deviate from those in local ancestry inference reference panels
and where the local ancestry of the testing cohort is difficult to infer — for instance,
due to deep or complex admixture events that have resulted in highly fragmented
ancestry tracts[25,26].
450
In conclusion, our method provides a new option to treat the ancestry information as
a continuous variable and interpolate a harmonized PRS for diverse ancestries.
Notably, although our method was developed primarily to calculate PRS when the
matched fine-tuning datasets were unavailable, our research showed that
successfully interpolating PRS required sufficient input data and highlighted the need
to collect genetic data for underrepresented populations. We believe that more
diverse and larger data collected in the coming future will enable the development of
new methods of interpolating PRS and the elucidation of the genetic basis of
complex traits.
460
461

Methods

Methodological Details of DiscoDivas

DiscoDivas interpolates PRS of testing individuals of diverse ancestry according to
the testing individual's PRS calculated using the PRS model fine-tuned in a few
single-ancestry fine-tuning datasets and genetic distance information. The pipeline
consists of two parts: harmonizing the input PRS data and interpolating the PRS.
468

Data harmonization
To reduce the bias in the interpolation, the PRS and PCA information should be in a
unified and harmonized scale. First, all the individuals in the fine-tuning datasets and
the testing dataset are projected in the same PCA space based on balanced
reference data covering the global genetic ancestry continuum. The reference data is
essential to avoid skewed correlation between the genotypic similarity and the
genetic distance, and to ensure that the PCA Euclidean distance can present
consistent genetic distance. The results presented in this study were based on PCA
calculated using pruned SNPs of 1000 Genomes[31] samples. A detailed description of
calculating PCA and Euclidean distance in this research is provided in the
supplementary section entitled 'Calculation of 1000 Genomes-based PCA and
Euclidean distance.'
481
482 Second, all the PRS input should be transferred to a comparable scale. We
483 regressed out the top 10 PCs from the PRS and then standardized the PRS residuals
484 to mean = 0 and standard deviation = 1.
485

486 **PRS interpolation**
487 The overall mathematical model of DiscoDivas is a linear combination of PRS based

488   on the PRS model fine-tuned in different fine-tuning datasets:

$$PRS_i = a_i \sum w_{i,k} PRS_{i,k}$$

where $PRS_{i,k}$ is the normalized PRS of individual *i* trained in fine-tuning dataset *k;*

$w_{i,k}$ is the interpolation coefficient which is a function of genetic distance between

the individual *i* and dataset *k* and other factors. a_i is a constant for individual *i* so that

$\sum a_i \, w_{i,k} = 1$.

The essential factor contributing to $w_{i,k}$ is the reciprocal of D_{i-k} , the genetic distance

between individual *I* and dataset *k*, so that the interpolation is basically linear. In the

ideal situation where all the fine-tuning samples are independent and generate PRS

of the same level of accuracy, the genetic distance between the testing individuals

and fine-tuning datasets is the only contribution factor and we define:

$w_{i,k} \equiv \frac{1}{D_{i-k}}$.

However, considering the more realistic scenarios where the fine-tuning samples

may be correlated and the PRS trained from different fine-tuning datasets may be of

different accuracies, we introduce two parameters:

1) d_k: tuning parameters based on the genetic distance / correlation between

504   the training datasets.

505   2) r_k: tuning parameter that represent the accuracy of the PRS fine-tuned in

506   sample *k;*

507   so that the overall interpolation coefficient is

$$w_{i,k} \equiv \frac{1}{D_{i-k}} \, d_k \, r_k$$

508   The final model of DiscoDivas is

$$PRS_i = a_i \sum \frac{1}{D_{i-k}} \, d_k \, r_k \, PRS_{i,k}$$

510   Here we propose the default method for calculating d_k and r_k:

511   d_k is based on the genetic distance matrix G in which each row and column

512   represent a fine-tuning sample, and the element $D_{l,k}$ is genetic distance between the

513   samples l and k, with diagonal ones being zero:

$$G = \begin{pmatrix} 0 & D_{1,2} & \cdots & D_{1,k} \\ D_{1,2} & 0 & & D_{2,k} \\ \vdots & & \ddots & \vdots \\ D_{1,k} & D_{2,k} & \cdots & 0 \end{pmatrix}$$

The shrinkage follows the similar principle of correcting marginal SNP effect size by

inverse of the LD matrix, which captures the correlation structure among SNPs.

Analogously, since genetic distance reflects the correlation between PRS models, its

inverse can be used to inform the degree of adjustment needed when combining or

interpolating PRS models across ancestries. The vector of shrinkage parameter d_k is

only derived from G^{-1}:

$$\vec{d} = G^{-1} \vec{1}$$

, where $\vec{1}$ is a vector of the same length as $\vec{d}$ and with all the elements being 1. r_k is

based on the accuracy of the PRS fine-tuned in the sample k.

Different options to decide the value of r_k

Under the additive assumption, the maximum accuracy of a PRS is achieved when the PRS R^2 approximates narrow-sense heritability h^2 and the PRS is saturated (namely, adding more samples in the Discovery GWAS would not further increase the PRS accuracy if other conditions remain the same). Previous research used percentage of heritability explained to present the accuracy of the PRS so that PRS predicting traits of different heritability and binary traits of different prevalence can be compared[48,49]. Here we recommend using the proportion of narrow-sense SNP heritability in the target sample explained by the PRS as the first choice of r_k

$$r_k = \sqrt{\frac{R_{PRS}^2}{h^2}}$$

However, the accurate estimation of h^2 requires sufficient sample size, which may not always be available for the individual-level data. If h^2 is unknown or cannot be accurately estimated, we provided an alternative approach that approximates the PRS given that most of the PRS is far from saturation and the accuracy of the PRS is roughly linearly correlated with the sample size of the discovery GWAS N_k, we combine the information from different samples in a similar way by combining Z scores in fixed-effect size meta-analysis:

$$r_k = \sqrt{N_{k\ discovery}}$$

If the trait or genetic ancestry used in the discovery GWAS does not match that of the fine-tuning and testing datasets, which collectively referred to as the 'target data,' the PRS accuracy also depends on the heritability of the trait in the discovery GWAS $h_{k\ discovery}^2$ and the genetic correlation between the discovery GWAS trait and the target trait $rg_{k\ discovery-target}$,

$$r_k = \sqrt{N_{k\ discovery} * h_{k\ discovery}^2 * rg_{k\ discovery-target}}$$

In a common and more ideal scenario where discovery data comes from multiple GWAS from different genetic ancestries and of decent statistical power for each genetic ancestry yet the heritability of the target trait in the fine-tuning sample is unknown or cannot be accurately estimated, the accuracy of the PRS fine-tuned in each single-ancestry fine-tuning sample is hard to estimate but is likely of similar accuracy. Therefore r_k can be omitted or equivalently set to a default constant value of 1.

In the DiscoDivas script provided, the r_k is set to be the default value 1 unless defined by the user otherwise, a_i, D_{i-k}, d_k is automatically calculated from the PCA information provided by the user.

Data

UK Biobank

The UK Biobank (UKBB) is a volunteer sample of approximately 500,000 adults aged 40-69 upon enrollment living in the United Kingdom recruited since 2006[50]. UKBB data used in this research were first QC'ed with the following process: Remove the individuals meeting the criteria that indicate low genotype quality or contamination: 1) have missing genotype rate larger than 0.02; 2) have genotype-phenotype sex discordance; 3) are identified as having excess heterozygosity and missing rates; 4) are identified as putatively carrying sex chromosome configurations that are not either XX or XY; 5) appeared to have unreasonably large numbers of relatives. From

the remaining samples, only one individual from a group of multiple individuals that
are closer than 3rd-degree relatives was retained. 415,402 individuals were left after
the QC. 390,037 were self-identified as EUR, 7,039 AFR, 8,652 non-Chinese Asian
(ASN), 1430 Chinese (CHN) and 6572 unknown or not answered, and 1672 as
admixed (MIX). The genetic ancestry referred from PC was largely correlated with
the self-reported race, with 385,038 EUR, 7,450 AFR, 8,298 SAS, 2,163 EAS, 669
AMR and 11,784 other (OTH) or admixed.
574
In the PRS test, UKBB samples were grouped by their genetic ancestry (see section
'Genetic ancestry inference'). The fine-tuning datasets for the single-ancestry
populations (AFR, EAS, EUR and SAS) were based on 1300 randomly selected
samples whose self-report ancestry matched with their genetic ancestry and the
probability of random forest = 1. The fine-tuning dataset for admixed ancestry (OTH)
is 1300 randomly selected samples of individuals of OTH genetic ancestry (see
Supplementary Figure 3). AMR didn't have its corresponding fine-tuning dataset due
to its small sample size, and we used OTH fine-tuning datasets as a proxy since the
two genetic ancestries had similar PCA. The remaining individuals of UKBB were
used as testing data.
585
The quantitative trait of the UKBB samples was the first measurement collected after
enrollment. The lipid trait measurement was adjusted for cholesterol-lowering
medication by dividing TC by 0.8 and LDL by 0.7 as before[51]. Cases of coronary
artery diseases (CAD) are defined using the definition described previously[24]; Cases
of type 2 diabetes (T2D) were defined as meeting any of the followings: 1) ICD-10 of
E11 or self-reported diagnosis of diabetes with available T2D first diagnosis date, or
2) HbA1C $\geq$ 6.5%, or 3) insulin use at enrollment, or 4) use of oral glucose-lowering
medication excl. isolated Metformin prescription at enrollment; controls were defined
as 1) without any diabetes or prediabetes, and 2) HbA1c < 5.7%. Cases of Type 1
Diabetes (1) ICD of E10 or self-report diagnosis of DM with first diagnosis date of
type 1 diabetes; and 2) insulin initiation within 1 year of diagnosis and 3) insulin use
at enrollment), prediabetes (without diabetes and HbA1c $\geq$ 5.7% and HbA1c < 6.5%)
were excluded.
599
600 UKBB participants provided consent in accordance with the primary IRB protocol,
601 and the Massachusetts General Hospital IRB approved the present secondary data
602 analysis of the UKBB data under UKBB application 7089.
603

Mass General Brigham Biobank
The Mass General Brigham Biobank (MGBB) is a volunteer sample of approximately
142,000 participants receiving medical care in the Mass General Brigham health care
system recruited starting 2010. 53,306 MGBB participants underwent genotyping via
Illumina Global Screening Array (Illumina, CA). MGBB genotype data was quality
controlled, imputed and assigned one of the populations AFR, AMR, EAS, EUR, SAS
using K-nearest neighbor model as described previously[52]. The phenotype data of
CAD and diabetes are drawn from PheCodes based on International Classification of
Diseases codes, Ninth (ICD9)110 and Tenth (ICD10) revisions, from the EHR as
described previously [52]. MGBB participants provided consent in accordance with the
primary IRB protocol, and the Massachusetts General Hospital IRB approved the
present secondary data analysis.
616

All of Us Research Program
The *All of Us* (AoU) Research Program is a volunteer sample of more than one
million United States residents recruited starting 2016. AoU aims to engage

communities previously underrepresented in biomedical research in the United
States and beyond[53]. In the present analysis, genetic data from the v7 245,394
participants who were genotyped using short read whole genome sequencing
(srWGS) data. Hapmap3 SNPs were extracted for the callset with the threshold of
(AF) > 1% or population-specific allele count (AC) > 100. Related individuals were
pruned according to the information provided by AoU. Due to the inclusive data
collection, we didn't exclude individuals whose self-report gender were different with
their assigned sex at birth and used the combination of self-report gender and
assigned sex as one of the covariates. The predicted ancestry information was
provided by AoU[54]. The phenotypes were defined as described in previous research
by Buu *et al*[32].
631

Simulated data

632
The simulated GWAS summary statistics were based on simulated genotype data
based on 1000 Genomes reference[6]. Only Hapmap3 SNPs were included in the
simulation. Causal SNPs were randomly selected from the Hapmap3 SNPs and
simulated per allele effect size following normal distribution. The non-genetic factor
was set to follow the same normal distribution across populations. The ladder of
causal SNP number was 100, 1000, 3000, 10000 and the heritability in each of the
population was 0.6. The causal SNP effect size was simulated as either constant
across populations or varying linearly in the PCA space.
641
642 The phenotype is the sum of genetic burden and non-genetic factor:

$$phenotype_i = \sum \beta_j x_{j,i} + E_i$$

643 where the $phenotype_i$ and E_i were the phenotype and non-genetic factor of individual
644 i; β_j was the effect size of causal SNP j, and $x_{j,i}$ was the number of risk alleles of
645 individual i in SNP j.
646
We used the PLINK2[28] to calculate the genetic burden based on the simulated causal
SNPs and effect size and used R to simulate the non-genetic factors by generating a
normal distribution, scale the genetic burden and non-genetic factor, and generate a
phenotype of heritability set to be 0.6. We used up to 100k individuals per population
to generate the summary statistical GWAS as the discovery data for the PRS test.
The rest simulated data were left out for the fine-tuning and testing datasets. The
summary statistics GWAS were generated based on the simulated genotype data
and phenotype data using the '--glm' function of PLINK2.
655
In addition to the completely simulated data, we generated more realistic fine-tuning
and testing datasets of a wider genetic ancestry range by using the QC'ed genotype
data from UKBB described in the section 'Biobank data.' We simulated the genetic
burden, non-genetic factor, and phenotype based on the real-life UKBB genotype
data with the same pipeline and parameters. A more detailed description of
simulating the data were given in section 'Generating data for simulation analysis' in
the supplementary text.
663

Data Availability

The access to biobank data (UK Biobank, Mass General Brigham Biobank, and All of
US Research Program) were gained upon application. The simulated genotype data
based on 1000 Genomes were downloaded from

https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/COXHAP
;The resource of summary statistics GWAS data used to generate PRS were given in
the supplementary file. The 1000 Genome raw reference genotype data were
downloaded from https://cncr.nl/research/magma/.
672

Code Availability

674 The scripts of running DiscoDivas and other supporting files can be found at
675 https://github.com/YunfengRuan/DiscoDivas; PRS-CS:
676 https://github.com/getian107/PRScs; LDpred2:
677 https://privefl.github.io/bigsnpr/articles/LDpred2; PLINK2: https://www.cog-
678 genomics.org/plink/2.0/.
679
680

Acknowledgements

We thank the participants and staff of the UK Biobank (application 7089), Mass
General Brigham Biobank, and *All of Us* Research Program. We thank Ying Wang,
Paul O'Reilly, Raymond Walters for helpful discussion and advice. P.N. is supported
by NHGRI U01HG011719 and NHLBI R01HL127564. N.C is supported by NHGRI
U01HG011719 and R01HG010480. A.P.P. is supported by NHLBI K08HL168238.
S.M.C. is supported by NHLBI K099HL177340.

Author Contributions

Y.R. and P.N. designed the project; Y.R. developed the statistical methods and
programmed the code for DiscoDivas. A.P curated the summary statistical GWAS.
R.B, S.K, L.H, B.T, S.M.C., and W.H participated in application for the access to the
Biobank data and the data curation. Y.R and R.B performed the data analysis. R.B,
B.T, H.Z, and N.C contributed to the method development. Y.R. and P.N wrote the
manuscript. A.P. and N.C. provided critical revision for the manuscript. All the authors
reviewed and approved the final version of the manuscript.
697

Declaration of interests

P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific,
Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca,
Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts,
CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital,
Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck,
Novartis, Novo Nordisk, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela,
Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal
employment at Vertex Pharmaceuticals, all unrelated to the present work. All other
authors report no conflicts.

Reference

1. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may
exacerbate health disparities. *Nat Genet* **51**, 584–591 (2019).
2. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-
ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**,
832 (2023).
3. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse
populations. *Nat Genet* **54**, 573–580 (2022).
4. Jin, J. *et al.* MUSSEL: Enhanced Bayesian Polygenic Risk Prediction
Leveraging Information across Multiple Ancestry Groups. *bioRxiv*
2023.04.12.536510 (2023) doi:10.1101/2023.04.12.536510.
5. Patel, A. P. *et al.* A multi-ancestry polygenic risk score improves risk prediction
for coronary artery disease. *Nat Med* **29**, 1793–1803 (2023).
6. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves
performance across diverse populations. *Nat Genet* **55**, 1757–1768 (2023).
7. Ding, Y. *et al.* Polygenic scoring accuracy varies across the genetic ancestry
continuum. *Nature* **618**, 774–781 (2023).
8. Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L. & Bonham, V. L. Lack Of
Diversity In Genomic Databases Is A Barrier To Translating Precision
Medicine Research Into Practice. *Health Aff* **37**, 780–785 (2018).
9. The All of Us Research Program Genomics Investigators. Genomic data in the
All of Us Research Program. *Nature* **627**, 340–346 (2024).
10. Fatumo, S. *et al.* Polygenic risk scores for disease risk prediction in Africa:
current challenges and future directions. *Genome Medicine* vol. 15 Preprint at
https://doi.org/10.1186/s13073-023-01245-9 (2023).
11. Dokuru, D. R., Horwitz, T. B., Freis, S. M., Stallings, M. C. & Ehringer, M. A.
South Asia: The Missing Diverse in Diversity. *Behav Genet* **54**, 51–62 (2024).
12. Stefflova, K. *et al.* Dissecting the Within-Africa ancestry of populations of
African descent in the Americas. *PLoS One* **6**, (2011).
13. Harlemon, M. *et al.* A custom genotyping array reveals population-level
heterogeneity for the genetic risks of prostate cancer and other cancers in
Africa. *Cancer Res* **80**, 2956–2966 (2020).
14. Anagnostou, P. *et al.* Inter-individual genomic heterogeneity within European
population isolates. *PLoS One* **14**, (2019).
15. Pan, Z. & Xu, S. Population genomics of East Asian ethnic groups. *Hereditas*
vol. 157 Preprint at https://doi.org/10.1186/s41065-020-00162-w (2020).
16. Khera, A. V *et al.* Whole-Genome Sequencing to Characterize Monogenic and
Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial
Infarction. *Circulation* **139**, 1593–1602 (2019).
17. Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in
diverse human populations. *Nat Commun* **10**, 3328 (2019).
18. Wang, M. *et al.* Validation of a Genome-Wide Polygenic Score for Coronary
Artery Disease in South Asians. *J Am Coll Cardiol* **76**, 703–714 (2020).
19. Ge, T. *et al.* Development and validation of a trans-ancestry polygenic risk
score for type 2 diabetes in diverse populations. *Genome Med* **14**, 70 (2022).
20. O'Sullivan, J. W. *et al.* Polygenic Risk Scores for Cardiovascular Disease: A
Scientific Statement From the American Heart Association. *Circulation* vol. 146
E93–E118 Preprint at https://doi.org/10.1161/CIR.0000000000001077 (2022).

21. Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to
clinical instruments. *Genome Medicine* vol. 12 Preprint at
https://doi.org/10.1186/s13073-020-00742-5 (2020).

22. Xiang, R. *et al.* Recent advances in polygenic scores: translation, equitability,
methods and FAIR tools. *Genome Medicine* vol. 16 Preprint at
https://doi.org/10.1186/s13073-024-01304-9 (2024).

23. Marnetto, D. *et al.* Ancestry deconvolution and partial polygenic score can
improve susceptibility predictions in recently admixed individuals. *Nat
Commun* **11**, (2020).

24. Sun, Q. *et al.* Improving polygenic risk prediction in admixed populations by
explicitly modeling ancestral-differential effects via GAUDI. *Nat Commun* **15**,
(2024).

25. Sun, Q. *et al.* Opportunities and challenges of local ancestry in genetic
association analyses. *American Journal of Human Genetics* vol. 112 727–740
Preprint at https://doi.org/10.1016/j.ajhg.2025.03.004 (2025).

26. Oliveira, S., Marchi, N. & Excoffier, L. Assessing the limits of local ancestry
inference from small reference panels. *Mol Ecol Resour* **24**, (2024).

27. Zhao, Z. *et al.* One score to rule them all: regularized ensemble polygenic risk
prediction with GWAS summary statistics. *BioRxiv* Preprint at
https://doi.org/10.1101/2024.11.27.625748 (2024).

28. Privé, F. *et al.* Portability of 245 polygenic scores when derived from the UK
Biobank and applied to 9 ancestry groups from the same cohort. *Am J Hum
Genet* **109**, 12–23 (2022).

29. Bitarello, B. D. & Mathieson, I. Polygenic scores for height in admixed
populations. *G3: Genes, Genomes, Genetics* **10**, 4027–4036 (2020).

30. Prive, F. Using the UK Biobank as a global reference of worldwide populations:
Application to measuring ancestry diversity from GWAS summary statistics.
Bioinformatics **38**, 3477–3480 (2022).

31. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**,
68–74 (2015).

32. Truong, B. *et al.* Integrative polygenic risk score improves the prediction
accuracy of complex traits and diseases. *Cell Genomics* **4**, (2024).

33. Wang, Y. *et al.* Polygenic prediction across populations is influenced by
ancestry, genetic architecture, and methodology. *Cell Genomics* **3**, (2023).

34. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic
prediction via Bayesian regression and continuous shrinkage priors. *Nat
Commun* **10**, 1776 (2019).

35. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger.
Bioinformatics **36**, 5424–5431 (2021).

36. Chang, C. C. *et al.* Second-generation PLINK: Rising to the challenge of larger
and richer datasets. *Gigascience* **4**, (2015).

37. Atkinson, E. G. *et al.* Tractor uses local ancestry to enable the inclusion of
admixed individuals in GWAS and to boost power. *Nat Genet* **53**, 195–204
(2021).

38. Marnetto, D. *et al.* Ancestry deconvolution and partial polygenic score can
improve susceptibility predictions in recently admixed individuals. *Nat
Commun* **11**, (2020).

39. Xu, Y. *et al.* Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's
Disease (AD) on Rate of Change in Cognitive Function and AD-Related
Biomarkers Among Asymptomatic Individuals. *Journal of Alzheimer's Disease*
94, 1587–1605 (2023).

40. Tubbs, J. D. *et al.* Pathway-Specific Polygenic Scores Improve Cross-Ancestry
Prediction of Psychosis and Clinical Outcomes. Preprint at

https://doi.org/10.1101/2023.09.01.23294957 (2023).

41.   Miao, J. *et al.* Quantifying portable genetic effects and improving cross-
812   ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**,
813   (2023).

814   42.   Kumar, R., Bhattacharya, S. & Murmu, G. Exploring Optimality of Piecewise
815   Polynomial Interpolation Functions for Lung Field Modeling in 2D Chest X-Ray
816   Images. *Front Phys* **9**, (2021).

817   43.   Womersley, R. S. & Sloan, I. H. *How Good Can Polynomial Interpolation on*
818   *the Sphere Be? Advances in Computational Mathematics* vol. 14 (2001).

819   44.   Choudhury, A. *et al.* Population-specific common SNPs reflect demographic
820   histories and highlight regions of genomic plasticity with functional relevance.
821   *BMC Genomics* **15**, (2014).

822   45.   Rees, J. S., Castellano, S. & Andrés, A. M. The Genomics of Human Local
823   Adaptation. *Trends in Genetics* vol. 36 415–428 Preprint at
824   https://doi.org/10.1016/j.tig.2020.03.006 (2020).

825   46.   Mas-Sandoval, A., Mathieson, S. & Fumagalli, M. The genomic footprint of
826   social stratification in admixing American populations. **12**, 84429 (2023).

827   47.   Patel, R. A. *et al.* Genetic interactions drive heterogeneity in causal variant
828   effect sizes for gene expression and complex traits. *Am J Hum Genet* **109**,
829   1286–1297 (2022).

830   48.   O'Connor, L. J. The distribution of common-variant effect sizes. *Nat Genet* **53**,
831   1243–1249 (2021).

832   49.   Zhang, Y., Qi, G., Park, J. H. & Chatterjee, N. Estimation of complex effect-
833   size distributions using summary-level statistics from genome-wide association
834   studies across 32 complex traits. *Nat Genet* **50**, 1318–1326 (2018).

835   50.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and
836   genomic data. *Nature* **562**, 203–209 (2018).

837   51.   Graham, S. E. *et al.* The power of genetic diversity in genome-wide
838   association studies of lipids. *Nature* **600**, 675–679 (2021).

839   52.   Koyama, S. *et al.* Decoding Genetics, Ancestry, and Geospatial Context for
840   Precision Health. *medRxiv* (2023) doi:10.1101/2023.10.24.23297096.

841   53.   Kathiresan, N. *et al.* Representation of Race and Ethnicity in the
842   Contemporary US Health Cohort All of Us Research Program. *JAMA Cardiol* **8**,
843   859–864 (2023).

844   54.   Bick, A. G. *et al.* Inherited causes of clonal haematopoiesis in 97,691 whole
845   genomes. *Nature* **586**, 763–768 (2020).